The University of Cincinnati AIDS Clinical Trials Unit (UC ACTU) intends to continue its contributions to the AIDS Clinical Trials Group under the direction of its Project Leader, Robert Schooley, M.D. The AIDS Clinical Trials Group is the largest and most sophisticated clinical trials network in the world, and thus is in a unique position to concurrently advance pathophysiologic understanding of HIV disease while developing management strategies for HIV infection and its complications. The research agenda of the AIDS Clinical Trials Group will change as the knowledge base expands. As a participant in this process, the Cincinnati ACTU will:
Aim #1 Continue to perform a broad range of clinical trials and substudies to assure maximum Cincinnati ACTU contribution to the objectives of the ACTG research agenda, Aim #2 Identify barriers to minority enrollment at the Cincinnati ACTU and methods for overcoming them, Aim #3 Continue the research emphasis of the Cincinnati ACTU on Pneumocystis carinii by bringing recent basic science advances into the clinical trials arena, Aim #4 Develop the University of Cincinnati Mycology Center into a resource for the ACTG to study the pathobiology of fungal infection in the context of clinical trials.
Aim #1 will be accomplished by enrolling approximately 200 subjects per year into clinical trials and their substudies. The UC ACTU will continue its excellent performance in clinical trials accrual, retention, and data management.
Aim #2 will be met by developing a specific Minority Recruitment Program with goals and objectives and testable hypotheses. By June 1997, the project will have generated specific data regarding the efficacy of various interventions for minority enrollment.
Aim #3 will be achieved by continuing the activities of the world class Pneumocystis research team that has developed at the UC ACTU under the direction of Dr. Peter Walzer which includes basic scientists and clinicians working together toward a common goal.
Aim #4 will be achieved by developing a clinical/basic science collaborative effort using the model of the Pneumocystis research team, and taking advantage of the large number of well established basic scientists in mycology and combining them with the excellent clinical program of the UC ACTU.
|Grady, Benjamin J; Torstenson, Eric S; McLaren, Paul J et al. (2011) Use of biological knowledge to inform the analysis of gene-gene interactions involved in modulating virologic failure with efavirenz-containing treatment regimens in ART-naïve ACTG clinical trials participants. Pac Symp Biocomput :253-64|
|Sherman, Kenneth E; Rouster, Susan D; Stanford, Sandra et al. (2010) Hepatitis C virus (HCV) quasispecies complexity and selection in HCV/HIV-coinfected subjects treated with interferon-based regimens. J Infect Dis 201:712-9|
|Bhattacharya, Debika; Umbleja, T; Carrat, F et al. (2010) Women experience higher rates of adverse events during hepatitis C virus therapy in HIV infection: a meta-analysis. J Acquir Immune Defic Syndr 55:170-5|
|Zhao, Yu; Navia, Bradford A; Marra, Christina M et al. (2010) Memantine for AIDS dementia complex: open-label report of ACTG 301. HIV Clin Trials 11:59-67|
|Fichtenbaum, Carl J; Yeh, Tzu-Min; Evans, Scott R et al. (2010) Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087. J Clin Lipidol 4:279-87|
|Winham, Stacey J; Slater, Andrew J; Motsinger-Reif, Alison A (2010) A comparison of internal validation techniques for multifactor dimensionality reduction. BMC Bioinformatics 11:394|
|Butt, Adeel A; Tsevat, Joel; Leonard, Anthony C et al. (2009) Effect of race and HIV co-infection upon treatment prescription for hepatitis C virus. Int J Infect Dis 13:449-55|
|Tsevat, Joel; Leonard, Anthony C; Szaflarski, Magdalena et al. (2009) Change in quality of life after being diagnosed with HIV: a multicenter longitudinal study. AIDS Patient Care STDS 23:931-7|
|Skowron, Gail; Spritzler, John G; Weidler, Jodi et al. (2009) Replication capacity in relation to immunologic and virologic outcomes in HIV-1-infected treatment-naive subjects. J Acquir Immune Defic Syndr 50:250-8|
|Velilla, P A; Shata, M T; Lages, C S et al. (2008) Effect of low-dose IL-2 immunotherapy on frequency and phenotype of regulatory T cells and NK cells in HIV/HCV-coinfected patients. AIDS Res Hum Retroviruses 24:52-61|
Showing the most recent 10 out of 123 publications